CD24 overexpression in cancer development and progression: A meta-analysis

Oncology Reports

Volumn 22, Issue 5, 2009, Pages 1149-1156

  Lee, Ju Han ^a   Kim, Seo Hee ^a   Lee, Eung Seok ^a   Kim, Young Sik ^a  

^a Korea University College of Medicine   (South Korea)

Author keywords

Carcinoma; CD24; Meta analysis; Prognosis

Indexed keywords

CD24 ANTIGEN;

ADVANCED CANCER; ARTICLE; BILE DUCT CARCINOMA; BREAST CARCINOMA; CANCER GRADING; CANCER GROWTH; CANCER INVASION; CANCER RISK; CANCER STAGING; CARCINOGENESIS; CLINICAL TRIAL; DIGESTIVE SYSTEM CANCER; DISEASE ASSOCIATION; FEMALE GENITAL TRACT CANCER; GENE OVEREXPRESSION; HUMAN; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; META ANALYSIS; ONCOGENE; OVERALL SURVIVAL; PANCREAS CARCINOMA; PRIORITY JOURNAL; PROGNOSIS; PROSTATE CARCINOMA; SKIN CARCINOMA; URINARY TRACT CARCINOMA;

ANTIGENS, CD24; DISEASE PROGRESSION; FEMALE; HUMANS; LYMPHATIC METASTASIS; NEOPLASMS; PROGNOSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 70449366079     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or_00000548     Document Type: Article

References (39)

1. Kristiansen G, Sammar M and Altevogt P: Tumour biological aspects of CD24, a mucin-like adhesion molecule. J Mol Histol 35: 255-262, 2004.
2. Sagiv E and Arber N: The novel oncogene CD24 and its arising role in the carcinogenesis of the GI tract: from research to therapy. Expert Rev Gastroenterol Hepatol 2: 125-133, 2008.
3. Lim SC: CD24 and human carcinoma: tumor biological aspects. Biomed Pharmacother 59 (Suppl 2): 351-354, 2005.
4. Chappel MS, Hough MR, Mittel A, Takei F, Kay R and Humphries RK: Cross-linking the murine heat-stable antigen induces apoptosis in B cell precursors and suppresses the anti-CD40-induced proliferation of mature resting B lymphocytes. J Exp Med 184: 1639-1649, 1996.
5. Fogel M, Friederichs J, Zeller Y, Husar M, Smirnov A, Roitman L, Altevogt P and Sthoeger ZM: CD24 is a marker for human breast carcinoma. Cancer Lett 143: 87-94, 1999.
6. Kristiansen G, Winzer KJ, Mayordomo E, Bellach J, Schluns K, Denkert C, Dahl E, Pilarsky C, Altevogt P, Guski H and Dietel M: CD24 expression is a new prognostic marker in breast cancer. Clin Cancer Res 9: 4906-4913, 2003.
7. Surowiak P, Materna V, Paluchowski P, Matkowski R, Wojnar A, Maciejczyk A, Pudelko M, Kornafel J, Dietel M, Kristiansen G, Lage H and Zabel M: CD24 expression is specific for tamoxifen-resistant ductal breast cancer cases. Anticancer Res 26: 629-634, 2006.
8. Bircan S, Kapucuoglu N, Baspinar S, Inan G and Candir O: CD24 expression in ductal carcinoma in situ and invasive ductal carcinoma of breast: an immunohistochemistry-based pilot study. Pathol Res Pract 202: 569-576, 2006.
9. Lim SC and Oh SH: The role of CD24 in various human epithelial neoplasias. Pathol Res Pract 201: 479-486, 2005.
10. - phenotype is enriched in basal-like breast tumors. Breast Cancer Res 10: R53, 2008.
11. Athanassiadou P, Grapsa D, Gonidi M, Athanassiadou AM, Tsipis A and Patsouris E: CD24 expression has a prognostic impact in breast carcinoma. Pathol Res Pract 205: 524-533, 2009.
12. Kristiansen G, Denkert C, Schluns K, Dahl E, Pilarsky C and Hauptmann S: CD24 is expressed in ovarian cancer and is a new independent prognostic marker of patient survival. Am J Pathol 161: 1215-1221, 2002.
13. Choi YL, Kim SH, Shin YK, Hong YC, Lee SJ, Kang SY and Ahn G: Cytoplasmic CD24 expression in advanced ovarian serous borderline tumors. Gynecol Oncol 97: 379-386, 2005.
14. Surowiak P, Materna V, Kaplenko I, Spaczynski M, Dietel M, Kristiansen G, Lage H and Zabel M: Unfavorable prognostic value of CD24 expression in sections from primary and relapsed ovarian cancer tissue. Int J Gynecol Cancer 16: 515-521, 2006.
15. Santin AD, Zhan F, Bellone S, Palmieri M, Cane S, Bignotti E, Anfossi S, Gokden M, Dunn D, Roman JJ, O'Brien TJ, Tian E, Cannon MJ, Shaughnessy J Jr and Pecorelli S: Gene expression profiles in primary ovarian serous papillary tumors and normal ovarian epithelium: identification of candidate molecular markers for ovarian cancer diagnosis and therapy. Int J Cancer 112: 14-25, 2004.
16. Winkler A, Zigeuner R, Rehak P, Hutterer G, Chromecki T and Langner C: CD24 expression in urothelial carcinoma of the upper urinary tract correlates with tumour progression. Virchows Arch 450: 59-64, 2007.
17. Choi YL, Lee SH, Kwon GY, Park CK, Han JJ, Choi JS, Choi HY, Kim SH and Shin YK: Overexpression of CD24: association with invasiveness in urothelial carcinoma of the bladder. Arch Pathol Lab Med 131: 275-281, 2007.
18. Karahan N, Guney M, Oral B, Kapucuoglu N and Mungan T: CD24 expression is a poor prognostic marker in endometrial carcinoma. Eur J Gynaecol Oncol 27: 500-504, 2006.
19. Kim KH, Choi JS, Kim JM, Choi YL, Shin YK, Lee HC, Seong IO, Kim BK, Chae SW and Kim SH: Enhanced CD24 expression in endometrial carcinoma and its expression pattern in normal and hyperplastic endometrium. Histol Histopathol 24: 309-316, 2009.
20. Su MC, Hsu C, Kao HL and Jeng YM: CD24 expression is a prognostic factor in intrahepatic cholangiocarcinoma. Cancer Lett 235: 34-39, 2006.
21. Baumhoer D, Riener MO, Zlobec I, Tornillo L, Vogetseder A, Kristiansen G, Dietmaier W, Hartmann A, Wuensch PH, Sessa F, Ruemmele P and Terracciano LM: Expression of CD24, P-cadherin and S100A4 in tumors of the ampulla of Vater. Mod Pathol 22: 306-313, 2009.
22. Sagiv E, Memeo L, Karin A, Kazanov D, Jacob-Hirsch J, Mansukhani M, Rechavi G, Hibshoosh H and Arber N: CD24 is a new oncogene, early at the multistep process of colorectal cancer carcinogenesis. Gastroenterology 131: 630-639, 2006.
23. Weichert W, Denkert C, Burkhardt M, Gansukh T, Bellach J, Altevogt P, Dietel M and Kristiansen G: Cytoplasmic CD24 expression in colorectal cancer independently correlates with shortened patient survival. Clin Cancer Res 11: 6574-6581, 2005.
24. Chou YY, Jeng YM, Lee TT, Hu FC, Kao HL, Lin WC, Lai PL, Hu RH and Yuan RH: Cytoplasmic CD24 expression is a novel prognostic factor in diffuse-type gastric adenocarcinoma. Ann Surg Oncol 14: 2748-2758, 2007.
25. Kristiansen G, Schluns K, Yongwei Y, Denkert C, Dietel M and Petersen I: CD24 is an independent prognostic marker of survival in nonsmall cell lung cancer patients. Br J Cancer 88: 231-236, 2003.
26. Kristiansen G, Pilarsky C, Pervan J, Sturzebecher B, Stephan C, Jung K, Loening S, Rosenthal A and Dietel M: CD24 expression is a significant predictor of PSA relapse and poor prognosis in low grade or organ confined prostate cancer. Prostate 58: 183-192, 2004.
27. Sano A, Kato H, Sakurai S, Sakai M, Tanaka N, Inose T, Saito K, Sohda M, Nakajima M, Nakajima T and Kuwano H: CD24 expression is a novel prognostic factor in esophageal squamous cell carcinoma. Ann Surg Oncol 16: 506-514, 2009.
28. Lee HJ, Kim DI, Kwak C, Ku JH and Moon KC: Expression of CD24 in clear cell renal cell carcinoma and its prognostic significance. Urology 72: 603-607, 2008.
29. Droz D, Zachar D, Charbit L, Gogusev J, Chretein Y and Iris L: Expression of the human nephron differentiation molecules in renal cell carcinomas. Am J Pathol 137: 895-905, 1990.
30. Kwon GY, Ha H, Ahn G, Park SY, Huh SJ and Park W: Role of CD24 protein in predicting metastatic potential of uterine cervical squamous cell carcinoma in patients treated with radiotherapy. Int J Radiat Oncol Biol Phys 69: 1150-1156, 2007.
31. Jacob J, Bellach J, Grutzmann R, Alldinger I, Pilarsky C, Dietel M and Kristiansen G: Expression of CD24 in adenocarcinomas of the pancreas correlates with higher tumor grades. Pancreatology 4: 454-460, 2004.
32. Deichmann M, Kurzen H, Egner U, Altevogt P and Hartschuh W: Adhesion molecules CD171 (L1CAM) and CD24 are expressed by primary neuroendocrine carcinomas of the skin (Merkel cell carcinomas). J Cutan Pathol 30: 363-368, 2003.
33. Schabath H, Runz S, Joumaa S and Altevogt P: CD24 affects CXCR4 function in pre-B lymphocytes and breast carcinoma cells. J Cell Sci 119: 314-325, 2006.
34. Schindelmann S, Windisch J, Grundmann R, Kreienberg R, Zeillinger R and Deissler H: Expression profiling of mammary carcinoma cell lines: correlation of in vitro invasiveness with expression of CD24. Tumour Biol 23: 139-145, 2002.
35. - breast cancer cells exhibit enhanced invasive properties: an early step necessary for metastasis. Breast Cancer Res 8: R59, 2006.
36. low cells in breast cancer may not be associated with clinical outcome but may favor distant metastasis. Clin Cancer Res 11: 1154-1159, 2005.
37. Lee JH, Lee ES and Kim YS: Clinicopathologic significance of BRAF V600E mutation in papillary carcinomas of the thyroid: a meta-analysis. Cancer 110: 38-46, 2007.
38. + CD24(-) prostate cells are early cancer progenitor/stem cells that provide a model for patients with poor prognosis. Br J Cancer 98: 756-765, 2008.
39. Li C, Heidt DG, Dalerba P, Burant CF, Zhang L, Adsay V, Wicha M, Clarke MF and Simeone DM: Identification of pancreatic cancer stem cells. Cancer Res 67: 1030-1037, 2007.